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Colon cancer has the third highest incidence and mortality among cancers in the
United States. MicroRNA-21 (miR21) has been described as an oncomir that is highly
overexpressed in tumor tissue fromcolorectal cancer. Recent studies showed that silencing
of miR21 through use of a miR21 inhibitor (anti-miR21) affected viability, apoptosis and
the cell cycle in colon cancer cells. We identiﬁed an anti-miR21 that targets miR21 to
inhibit genes by both post-transcriptional gene silencing and transcriptional gene silencing
in the cytoplasm and nucleus, respectively. Overexpression of anti-miR21 in colon cancer
cells caused changes in miRNA expression levels. We found that treatment with anti-
miR21 down-regulated expression of miR30, which is involved in angiogenesis. In an in
vitro angiogenesis assay, network formation induced by an angiogenesis activator was
reduced upon treatment with anti-miR21. Sequence analysis of anti-miR21 and pri-miR30
revealed homology between anti-miR21 and the 3′ end of pri-miR30, suggesting that anti-
miR21may bind to pri-miR30 and block processing of the miRNA processing.These results
suggest anti-miR21 has a role not only in tumor growth but also in angiogenesis.Therefore,
treatment with the anti-miR21 antagomir may have a synergistic effect mediated through
suppression of miR30.
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INTRODUCTION
Colorectal cancer (CRC) is a major challenge worldwide (Parkin
et al., 2005) and is the third leading cause of cancer-related
death in the United States (Kemp et al., 2004). The incidence
of CRC has been increasing for decades, and although screen-
ing for CRC holds the promise of shifting the distribution of
detected cancers toward those in earlier stages (Gross et al., 2006),
surgery is still a cornerstone of CRC treatment. However, a con-
siderable fraction of CRC patients treated with surgery alone
will experience tumor recurrence. Therefore surgery is usually
accompanied by adjuvant chemotherapy. Patients with Stage II
CRC (no lymph node metastases or distant metastases) repre-
sent about 25% of all cases and have a 5-year overall survival
(OS) of 73–85%, when surgically respected (O’Connell, 2004).
Many efforts have been made to ﬁnd new therapeutic adjuvant
treatments.
MicroRNAs (miRNAs), which are small, noncoding, single-
stranded RNAs that are usually 20–22 nucleotides in length, have
been shown to play a role in CRC (Peters and Meister, 2007; Rana,
2007). miRNAs control gene expression by inducing the degrada-
tion or inhibiting the translation of target mRNAs by binding to
complementary sequences in the 3′-untranslated region (3′ UTR)
(Long andLahiri, 2011; Zhang et al., 2011). This 3′ binding inhibits
ribosome function, causing decapping of the capped 5′ end, dead-
enylation of the poly(A) tail and degradation of the target mRNA
(Filipowicz et al., 2008). In addition to being important regulators
of many biological processes such as the cell cycle, apoptosis,
proliferation, or invasiveness, miRNAs can also affect the efﬁcacy
of anticancer therapies (Hanahan and Weinberg, 2000). Recent
studies indicate that several miRNAs are differently expressed in
normal and neoplastic colon tissues and they can be used to dis-
tinguish colon cancers relative to the histopathologic, prognostic,
and predictive characteristics of the tumors (Hanahan and Wein-
berg, 2000; Slaby et al., 2007, 2009; Schetter et al., 2008; Chang
et al., 2011).
MicroRNA-21 (miR21) is one of the miRNAs that are fre-
quently overexpressed in CRC (Slaby et al., 2007; Schetter et al.,
2008; Nielsen et al., 2011) and is, therefore, considered an onco-
miRNA. Several studies have shown an association between
elevated levels of miR21 and the downregulation of tumor sup-
pressor genes, including programmed cell death 4 (PDCD4),
tissue inhibitor of metalloproteinase 3 (TIMP3; Selaru et al.,
2009), phosphatase and tensinhomolog (PTEN;Wang et al., 2011),
tropomyosin 1 (TPM1; Zhu et al., 2007), reversion-inducing
cysteine-rich protein (RECK; Ziyan et al., 2011), ras homolog
gene family member B (Liu et al., 2011), and maspin (Torres
et al., 2011). This has led to miR21 being considered a promis-
ing therapeutic target for treating CRC. As an approach toward
inhibiting miR21, we designed an anti-miR21 antagomir (com-
plementary to the miR21∗ sequence) that could inhibit miR21
(miRBase accession number: MIMAT0004494; Castanotto et al.,
2007).
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There is also mounting evidence that small RNAs, including
miRNAs, play important roles in the nucleus and that
some miRNAs, after being exported and post-transciptionally
processed in the cytoplasm, then return to the nucleus
(Politz et al., 2009). The nuclear sites and the functional
signiﬁcance of these nuclear-returning miRNAs are not
known.
Although several research groups are focused on deﬁning the
effects of anti-miR21 in blocking carcinogenesis, its effects in
CRC cells have not yet been determined. We sought to deci-
pher the mechanism of action of anti-miR21 in CRC cells
by quantifying the expression of various miRNAs and siRNAs
and determining the localization of miR21 and other miRNAs
within the cell. We found that anti-miR21 blocked the func-
tion of miR21 by acting within the nucleus to prevent miR21
from binding to the 3′ UTR of an EGFP target gene. Moreover,
anti-mir21 perturbed the levels of miR30, another endogenous,




Human CRC HCT116 cells were grown in Dulbecco’s mod-
iﬁed Eagle’s medium (DMEM) supplemented with 10%
fetal bovine serum (FBS), 100 units/ml penicillin, and
100 μg/ml streptomycin at 37◦C in 5% CO2. The
pcDNA4/GFPmir21 (Meister et al., 2004b) reporter has been
previously described (Castanotto et al., 2007). One day before
transfection, 1 × 106 HCT116 cells, stably expressing pcDNA4/
GFPmir21, were transfected with 100 nM anti-miR21
(5′-ACGGCAACACCAGUCGAUGGGCUGU-3′) using Lipofec-
tamine 2000 according to the manufacturer’s protocol for six-well
plates. EGFP expression was analyzed and documented using a
Nikon eclipse TE2000-S ﬂuorescence microscope and provided
software.
Human umbilical vein endothelial cells (HUVEC2; BD Bio-
science) were grown in EGMTM-2-MV bullet kitTM (Lonza) at
37◦C in 5% CO2 and used in experiments before passage ﬁve.
Cy3-labeled anti-miR21 was transfected into HUVEC2 cells with
RNAiMAX (50 nM, Invitrogen). Cy3-labeled siRNA was used as a
negative control. Angiogenesis assays were performed with an in
vitro angiogenesis assay kit (Abcam), according themanufacturer’s
instructions.
DETECTION OF miRNAs
TaqMan miRNA assays (Applied Biosystems) were used to
quantify miR21, miR20, miR28, and miR30 in CRC cells.
Brieﬂy, cDNA synthesis was carried out using the TaqMan
MicroRNA reverse transcription kit (Applied Biosystems). The
miRNA reverse transcription-PCR primers for miR21, miR20,
miR28, and miR30-5p, as well as the endogenous control
18s RNA, were purchased from Applied Biosystems. Real-
time qRT-PCR analysis was performed using a CFX96TM Real-
time PCR System (Bio-Rad). The PCR mix contained Taq-
Man 2× Universal PCR Master Mix and was incubated as
follows: 95◦C for 10 min followed by 95◦C for 15 s, 60◦C
for 60 s for up to 40 cycles. 18s RNA was used as the
internal standard to normalize miRNA expression. The rel-
ative quantity (RQ) of different miRNAs was calculated as
RQ = 2 − Ct.
SMALL RNA DEEP SEQUENCING
HCT116 cells were grown to 70–80% conﬂuence in DMEM
in 10-cm dishes 1 day prior to transfection. Cells were trans-
fected with 50 nM small RNAs through Lipofectamine 2000
methods (Invitrogen). At 48 h post-transfection, total RNAs
were isolated with TriZol reagent (Invitrogen). RNA was resus-
pended in water (6 μl) and the entire volume was added to
TruSeq Small RNA Sample reagents (Illumina). Samples were
ampliﬁed by 15 cycles of PCR, clustered in a single read v3
ﬂow cell, and deep sequenced for small RNA on a HiSeq
2000.
BIOINFORMATICS
All analysis was performed using the R statistical environment and
Bioconductor packages “Biostrings” and “ShortRead” (Morgan
et al., 2009). The sequences generated from Illumina Pipeline v1.6
were matched to siRNA sense and anti-sense sequences through
a seed-and-growth algorithm. First, sequences were searched
for a siRNA seed sequence of 16 nucleotides after removing
the 3′-adapter through the Bioconductor package “ShortRead.”
For example, for an siRNA sequence of 23 nucleotides, the
Illumina sequences were searched against eight seeds (i.e., sub-
sequences from bases 1–16, 2–17, and so on of the original
siRNA sequence). The matched sequences were then searched
against the siRNA sequence with one base added to the 5′-
end, one at a time until the sequence no longer perfectly
matched the siRNA subsequence. The same procedure was used
to grow the 3′-end of the matching sequence. When the growth
steps were ﬁnished, the additional bases at either end of the
sequence were considered as 5′ and 3′ that do not match the
siRNA. The ﬁnal matched sequences were reported by their
relative start and end positions on the siRNA sequence, the
non-matching bases at their ends, and the number of occur-
rences.
This set of sequences was then aligned along with each
siRNA reference sequence using the ClustalX2 multiple align-
ment tool (Larkin et al., 2007), not allowing gaps. The multiple
aligned sequences were visualized and exported using JalView
(Waterhouse et al., 2009).
CELL PROLIFERATION
Cellswere seeded into 96-wellmicrocultureplates (15,000 cells/well)
and transfected with 5 nM small RNAs or control siRNA through
Lipofectamine 2000 methods (Invitrogen). After 24 h incuba-
tion, CellTiter 96 Aqueous One Solution Reagent (20 μl; MTS;
Promega) was added to each well (into 100 μl of cell suspen-
sion). The plate was then incubated for 2 h at 37◦C. MTS assay
was used to measure cell viability. Speciﬁcally, the absorbance
of soluble formazan produced by cellular reduction of MTS
was measured at 490 nm. Values for the experimental con-
ditions were normalized to a control value of 100 for each
experiment.
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STATISTICAL ANALYSIS
All statistical analyzes were performed using a two-tailed unpaired
Student’s t-test.
RESULTS
EFFICIENCY OF ANTI-miR21 (ANTAGOMIR)
In a previous study, we constructed a stable clonal CRC cell
line that contains an integrated enhanced green ﬂuorescent pro-
tein (EGFP) gene that has a fully complementary target site
for miR21 in the 3′ UTR (HCT116-GFP) (Meister et al., 2004b;
Castanotto et al., 2007). In this cell line, expression of EGFP is
knocked down by the endogenous expression of miR21, which
is up-regulated in CRC (Slaby et al., 2007; Schetter et al., 2008).
HCT116-GFP cells transfected with anti-miR21 showed restored
expression of GFP at 24, 48, and 72 h after transfection, but we
did not detect GFP signal in cells transfected with control siR-
NAs (Figure 1A). To order to improve the image of the cell, we
took the cell picture with confocal microscopy. The activation of
GFP by anti-miR21 is shown in Figure 1B. These results con-
ﬁrmed that anti-miR21 can activate GFP translation by binding to
miR21 to block binding of miR21 to the 3′ UTR of EGFP in CRC
cells.
ANTI-miR21 EFFECT OCCURS, WHICH ACTIVATES GFP mRNA
EXPRESSION IN THE NUCLEUS
To determine whether the anti-miR21 could improve RNA and
protein level which showed the post-transcriptional gene silenc-
ing (PTGS), we examined the expression of EGFP protein and
mRNA in HCT116-GFP cells at 24, 48, and 72 h after transfection
with a range of concentrations of anti-miR21 (0.001–100 nM;
Figures 1C,D). Treatment with anti-miR21 increased the expres-
sion of EGFP protein in a dose- and time-dependent manner
(Figure 1C). Surprisingly, a high level of expression of GFP
mRNA was detected at 24 h (Figure 1D). To systematically deter-
mine where in the cell anti-miR21 inhibits miR21, nuclear and
cytoplasmic fractionswere isolated fromHCT116-GFP cells trans-
fected with the anti-miR21. Remarkably, expression of EGFP
was increased in the nuclear fractions containing anti-miR21
(Figure 1E). The separation of cytoplasm and nuclear protein
was conﬁrmed by western blot analysis for the nuclear protein
ﬁbrillarin (Figure 1F). Recently Nishi et al. (2013) showed that
miRNA-mediated gene silencing localizes to the nucleus. Our
results suggest that the antagomir blocks miR21 in the cytoplasm
and in the nucleus.
ANTI-miR21 SLIGHTLY AFFECTS THE DEGRADATION OF
ENDOGENOUS miR21
To establish whether the anti-miR21 acts by affecting miR21 lev-
els, we performed deep sequencing and TaqMan microRNA assay.
When miR21 was inhibited using the anti-miR21, the number
of total counts of sequences that matched miR21 reduced by
13% (Figure 2A). The levels of the complementary anti-miR21
sequence (miR21∗) were dramatically increased in anti-miR21
treated cells (Figure 2B). To validate the results of the deep
sequencing assay, we monitored the steady-state accumulation
of mature miR21 through a ﬂuorescent probe-coupled PCR
assay (TaqMan probe qPCR). Similar to the sequencing data,
levels of mature miR21 were 10% lower in anti-miR21-treated
HCT116 cells after transfection compared to mock transfected
cells (Figure 2C). These results indicate that the antagomir slightly
contributed to the degradation of endogenous miR21 in HCT 116
cells.
miRNAs ARE PERTURBED BY THE ANTI-miR21 ANTAGOMIR
Some miRNAs repress several positive regulators in a path-
way, whereas others target both positive and negative regulators,
to possibly buffer against minor physiological variations that
can trigger much larger changes in the physiology of the cell
(Khraiwesh et al., 2010). In CRC cells, this buffering role could
mean thatmiR21 simultaneously targets the PTEN,PDCD4, Spry-
1, and NF1B oncogenes. Furthermore, miRNAs can cooperate
with each other to regulate one or more pathways, which increases
the ﬂexibility of regulation (Papagiannakopoulos et al., 2008).
To determine whether the anti-miR21 could effectively perturb
another miRNA, we analyzed the expression of several miRNAs
in the deep sequencing results. This revealed that miR20, miR28
and miR30 were up-regulated in CRC cells that received mock
(Figures 3A–C). Yang et al. (2009) and Volinia et al. (2006) iden-
tiﬁed that miR21, miR20, and miR30 were highly expressed in
colon cancer. Interestingly, the expression of miR30 was signiﬁ-
cantly decreased in cells transfected with anti-miR21 (Figure 3C).
Analysis of the expression of miR20,miR28, andmiR30 using Taq-
Man qPCR (Figures 3D–F) revealed that the steady-state levels of
mature miR30 were decreased in cells transfected with anti-miR21
(Figure 3F). The down-regulation of miR30 by anti-miR21 indi-
cates that the anti-miR21 antagomir interferes with the stability of
another miRNA.
PERTURBATION OF miR30 BY THE ANTAGOMIR OCCURS IN THE
CYTOPLASM
The siRNAs or miRNAs transfected in the cell affected the up-
regulation of many mRNAs that were potentially targeted by
miRNAs. Khan et al. (2009) suggested that transfection of small
RNAs can reduce the endogenous miRNA function. To conﬁrm
the perturbation of miR30 by anti-miR21, we transfected HCT116
cells with a range of doses of anti-miR21 and measured miR30
expression by qPCR. When transfected at 0.001 nM, anti-miR21
led to an 80% reduction in the expression of miR30 (Figure 4A).
Previous studies have shown that RISC components are local-
ized at cytoplasmic foci of P-bodies that contain translationally
repressed mRNAs. In P-bodies, translationally repressed mRNAs,
which arise through PTGS, can remain in oligomeric structures
for storage or can form complexes with cap-binding proteins
and decapping enzymes, which triggers mRNA degradation. In
other words, miRNAs in miRISC complexes could provide the
sequence speciﬁcity for shuttling target mRNAs for storage or
degradation in P-bodies (Kedersha et al., 2005; Liu et al., 2005;
Valencia-Sanchez et al., 2006). We examined if mature miRNAs in
CRC cells localized to the nucleus or cytoplasm (Figures 4B–E).
miR20 and miR28, whose expression levels were not affected
by anti-miR21 (Figures 3A,B,D,E), showed the same expression
levels in the nucleus and cytoplasm in the presence or absence
of anti-miR21 treatment (Figures 4D,E). In contrast, miR21
and miR30, which were regulated by anti-miR21, predominantly
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FIGURE 1 | Effect of anti-miR21 on miR21 activity. (A) Bright ﬁeld
images of HCT116-GFP cells that were transfected with anti-miR21 or
control siRNA and grown for the indicated times. (B) left, confocal
microscopy image of HCT116-GFP cell 48 h after transfection with
anti-miR21. Hoechst33342 stain (blue) indicates nuclei. right, confocal
microscopy image of HCT116-GFP cell 48 h after transfection with control
siRNA. (C) Relative GFP ﬂuorescence of HCT116-GFP cells transfected with
anti-miR21 (0.001–10 nM). Values represent mean ± SD (n = 3) from three
independent experiments. (D) Quantitative GFP mRNA levels (normalized
by GAPDH), determined by Q-PCR, in HCT116-GFP cells transfected with
anti-miR21 (0.001–100 nM). (E) GFP mRNA levels in nuclear and
cytoplasmic extracts of HCT116-GFP cells transfected with control siRNA
and anti-miR21. MiRNA levels were determined as described in (D).
(F) Conﬁrmation of separation of nuclear and cytoplasmic fractions. Aliquots
containing 30 μg of total protein from cytoplasm and nuclear extracts were
separated by 12% SDS-PAGE gel, transferred onto nitrocellulose
membrane, and probed with antibodies speciﬁc for the nuclear protein
ﬁbrillarin.
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FIGURE 2 | Expression level of miR21 and miR21∗. Total counted number
of deep-sequencing reads containing a corresponding sequence to miR21
(A) and miR21∗. ∗ indicates the small RNA processed from the hairpin arm
opposite the mature miR21. (B) from HCT116-GFP cells transfected with
anti-miR21 or mock control. (C) Quantitative miR21 expression determined
byTaqMan probe Q-PCR of HCT116-GFP cells transfected with anti-miR21 or
mock control. Values represent mean ± SD (n = 3) of three independent
experiments.
FIGURE 3 | Regulation of miRNA expression by anti-miR21 in CRC.
Expression levels of miRNAs that had the highest counts in HCT116
deep-sequencing results. Total number of RNA sequence reads for
miR20 (A), miR28 (B), and miR30 (C) in HCT116-GFP cells transfected
with anti-miR21 and mock control. Normalized expression levels of
miR20 (D), miR28 (E), and miR30 (F) as determined by quantitative
PCR using miRNA taqman probes. Error bars indicate SD. ∗p < 0.05,
∗∗∗p < 0.001.
localized to the cytoplasm in cells treated with the antagomir
(Figures 4B,C).
To study the pattern of anti-miR21 localization in live cells, we
used confocal microscopy to image HCT116-GFP cells transfected
with Cy3-labeled anti-miR21. Anti-miR21 was largely seen in the
cytoplasm, but we also detected it in the nucleus (Figure 4F).
To verify the localization of anti-miR21 and pre-miR21 in the
cytoplasm and nucleus we co-transfected HCT116 cells with
Cy3-labeled pre-miR21 and anti-miR21; pre-miR21 can be pro-
cessed to mature miR21 in cells, so the Cy3 signal would indicate
the localization of miR21 in cells. Anti-miR21 strongly accumu-
lated in both the nucleus and cytoplasm, as evidenced by the
colocalization of Cy3-labeled anti-miR21 with the nuclear marker
DAPI (Figure 5A). Cy3-labeled pre-miR21 was mostly present
in the cytoplasm of HCT116 cells transfected with anti-miR21
(Figure 5B). Figures 5C,D of a nine-step Z-position sectional
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FIGURE 4 | Anti-miR21 changes the localization of miR30. (A) Abundance
of miR30 in HCT116-GFP cells transfected with anti-miR21 (0.01–10 nM), as
measured by real-time qPCR. Cytoplasmic or nuclear localization of miR21
(B), miR30 (C), miR20 (D), and miR28 (E) in cells transfected with anti-miR21
or mock control. (F) Confocal microscopy images showing the localization of
transfected anti-miR21 (red). GFP is shown in green and Hoechst33342 in
blue to indicate nuclei. The picture was taken by Zeiss LSM510 META
2-Photon microscope in Z-mode. Scale bars, 20 μm.
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FIGURE 5 | Localization of anti-miR21 and pre-miR21. Localization of
Cy3-labeled anti-miR21 (A) or Cy3-labeled pre-miR21 (B) (both red).
Nucleus indicated by DAPI (blue). The corresponding line scans were taken
over the area indicated by the arrow. Projections of the Z scans are
displayed for anti-miR21 (C) and pre-miR21 (D). Scale bar, 20 μm. Z-scan;
Depth, 9 μm.
scanning demonstrated the localization of anti-miR21 and pre-
miR21 in cytoplasm and nucleus. These results suggested that
miR21 is also mostly present in the cytoplasm of HCT116 cells
transfected with anti-miR21.
ANTI-miR21 INDUCES INHIBITION OF ANGIOGENESIS
Overexpression of miR30 in endothelial cells leads to increased
vessel number and length, and down-regulation of miR30 is
associated with inhibition of angiogenic pathways (Birdsey et al.,
2012). Both miR21 and miR30 are overexpressed in HUVECs
(Heusschen et al., 2010). Using an in vitro angiogenesis assay,
we saw a correlation between expression of anti-miR21 and
angiogenesis in HUVECs. We transfected HUVECs with Cy3-
labeled anti-miR21 and control siRNA, and then treated the
cells with an angiogenesis activator or inhibitor. Angiogenesis
activator Phorbol-12-myristate-13-acetate (PMA) enhanced the
ability of HUVEC to organize into tubular networks by induced
VEGF expression (Xu et al., 2008). Angiogenesis inhibitor JNJ-
10198409[(6,7-dimethoxy-2,4-dihydro-indeno [1,2-c]pyrazol-3-
yl)-(3-ﬂuro-phenyl) -amine] inhibited tyrosine kinase activity of
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FIGURE 6 | Effect of anti-miR21 on angiogenesis and cell survival. (A)
Confocal microscopy images of tubular formation of HUVEC2 cells transfected
with Cy3-labeled control siRNA or anti-miR21grown in the presence of an
angiogenesis inhibitor (JNJ-10198409; 0.3 μM) or activator (PMA; 0.6 μM). In
the merged image, Calcein AM is shown in green and Cy3-labeled anti-miR21
in red. The picture was taken by Zeiss AxioVert 200 inverted microscope.
Scale bars, 50 μm (B) Relative cell growths of HCT116-GFP cells that were
transiently transfected with negative control siRNA or anti-miR21 (5 nM). The
cells were allowed to grow for 2 days before MTS assay. Values are means of
four experiments ± SD. ∗∗∗p < 0.005 versus control.
growth factor receptors such as the platelet-derived growth fac-
tor (PDGF-BB; D’Andrea et al., 2005). After 1 day of treatment
with the activator or inhibitor, we stained cells with calcein AM,
and analyzed their shape and detected the Cy3 label to determine
the RNA localization (Figure 6). Cells failed in tube formation
when treated with the angiogenesis inhibitor and transfected with
control siRNA,mock or anti-miR21 (Figure 6A; lower area). How-
ever, HUVECs that were transfected with control siRNA or mock
treatment did form tubular networks when treated with PMA,
an angiogenesis-inducing agent. HUVECs transfected with anti-
miR21 displayed a decreased propensity to form tubular networks
of lesser length. This shape was similar to that of cells treated with
the angiogenesis inhibitor JNJ-10198409 (Figure 6A; upper area).
These results suggest that anti-miR21 down-regulated miR30, and
this reduced miR30 expression affected inhibition of angiogenesis.
To conﬁrm that anti-miR21 affects tumorigenesis in CRC we
used the MTS assay to assess cell growth. Cell proliferation was
reduced about 30% in anti-miR21-transfected cells as compared
with cells transfected with control siRNA (Figure 6B). These
results suggest that anti-miR21 inﬂuences cell growth in CRC.
siRNAs CANNOT COMPETE WITH ANTI-miR21
To determine if overexpressing other non-coding RNAs impaired
the function of miR21, we transfected HCT116-GFP cells with
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FIGURE 7 | siRNA did not controlled in miRNA. (A) Seed sequence (black
box) of with mature miR21 and the evaluated small RNAs. (B) Abundance of
miR21 in HCT116 cells transfected with DsiRNA B or siRNA B, as measured
by real-time qPCR. (C)Total number of reads corresponding to miR21 (black
bar) or miR21∗ (gray bar) in HCT116 cells transfected with DsiRNA A, siRNA
A, DsiRNA B or siRNA (B).
small interfering miR21 RNAs (siRNAs; Figure 7A). Using Taq-
Man qPCR, we detected expression of mature miR21 in the
transfected cells. Previous studies have shown that a 21mer short
hairpin RNA (shRNA) blocks the action of miR21 but a 25mer
shRNA does not (Grimm et al., 2006). In our system, neither the
21mer siRNA nor 25/27mer siRNAs affected miR21 expression
(qPCR data in Figure 7B and deep sequencing data in Figure 7C).
These results suggest that the siRNAs do not affect themechanisms
of miR21 transcription and processing or mRNA regulation.
DISCUSSION
The emerging signiﬁcance of miRNAs in cancer has spiked
major interest for possible use in cancer therapy, resulting in
many cancer-proﬁling studies of miRNAs. miR21 is greatly over-
expressed in CR colon cancer cells (Ambros, 2004), used target
of conventional cancer therapeutics and biomarker (Klooster-
man and Plasterk, 2006; Bushati and Cohen, 2007). Inhibition
of miR21 function by anti-miR21 has become an important and
widely used approach in therapeutic modalities of colon cancer
therapy. It is thought that the predominant function of miRNAs
is translational repression of target mRNAs (PTGS). A model of
RNA silencing suggests that the RISC complex can guide target
RNA cleavage or translational repression depending on the extent
of sequence complementarity between the miRNA and its target
(Meister et al., 2004a; Yi et al., 2005; Grimm et al., 2006; Castan-
otto et al., 2007). We have established that anti-miR21 regulates
miR21 in the nucleus by transcriptional gene silencing (TGS). This
is consistent with mounting evidence that miRNAs play impor-
tant roles in the nucleus (Hwang et al., 2007; Guang et al., 2008;
Kim et al., 2008; Marcon et al., 2008; Ohrt et al., 2008; Politz et al.,
2009; Nishi et al., 2013) and suggests that miR21 could lead to
an effect on gene silencing in the nucleus, and anti-miR21 can
inhibit this mechanism in nucleus. Consistent with our observa-
tion, it has been shown that activation of GFP RNA by anti-miR21
is caused in the nucleus (Figure 1E). We also demonstrated that
more anti-miR21 was present in the cytoplasm than in the nucleus
(Figures 4E and 5), suggesting there is not much need for miR21
to have lifted GFP down-regulation by anti-miR21 in the nucleus
(Figure 8A). Therefore, we hypothesize that anti-miR21 is not
only regulated at the post-transcriptional level, but is also subject
to ﬁne-tuning by a TGS mechanism. The potential role of nuclear
anti-miR21 in the regulation of gene transcription by inhibition
of miR21 expose a totally new and exciting application for cancer
therapy of small non-coding RANs.
It has been proposed that perturbation of miRNAs can cause
inference of miRNA regulatory network in cancer (Lujambio
and Lowe, 2012). Thus, perturbed levels of many miRNAs after
antagomir treatment can change the expression of many genes
that are involved in transcriptional repression, leading to unex-
pected outcomes. In principle, miRNAs repress several positive
components of a pathway, whereas others target both up- and
down- regulation, possibly to change against targeted mRNAs in
cytoplasm that could trigger much larger changes in the cells. Fea-
tured in this study is that reduced levels of miR30 by antagomir
of anti-miR21 can cause down-regulation of the miRNA-targeted
gene, which in turn can lead to unexpected effects. Indeed, anti-
miR21 led to decreased miR30 expression level, inhibiting tubular
forming ability in vitro (Figure 6A). Recent study is identifying
DLL4 as a target of miR30 and to demonstrate a key role for
miR30 in angiogenesis. The miR30 regulates angiogenesis through
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FIGURE 8 | Model for anti-miR21 activity. (A)TGS and PTGS models for
mechanism by which anti-miR21 inhibits miR21. (B) Model for mechanism by
which anti-miR21 inhibits miR30. Anti-miR21 blocks miR30 on the basis of
matching sequence. I. The structure of pri-miR30. Red bar indicates hybrid
area of anti-miR21, as identiﬁed by CLC Bio MainWorkbench software.
Highlighted sequence is mature miR30. II. Pri-miR30 is normally processed
into mature miR30 through the normal miRNA mechanism. III. The structure
of pri-miR30 can be changed by anti-miR21. IV. Sequence alignment of
pri-miR30 (upper sequence) with anti-miR21 (red sequence). Gray sequence
shows the mature miR30.
the highly conserved, molecular targeting of DLL4 (Bridge et al.,
2012). This, together with decreasing the expression of miR30 and
miR21 in endothelial cells, reduced the formation of cell networks
in vitro. Moreover, down-regulation of miR21 in colon cancer
cells leads to inhibition of cell proliferation (Figure 6B). These
results suggest that anti-miR21 inhibited oncogenesis by blocking
the activity of miR21 and regulated angiogenesis, which is critical
for supporting tumor growth, by perturbing miR30.
Our data indicate that anti-miR21 led to decreased miR30
expression level, inhibited angiogenesis in vitro. Several pos-
sibilities exist for this situation. One of this is small RNA
perturbation with small RNA competition for RISC complex.
Transfection with small RNAs or miRNAs can disturb the func-
tion of endogenous miRNA, probably by saturating the RISC
pathway (Khan et al., 2009). For example, exogenous small
RNAs can compete for endogenous RISC components required
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for miRNA processing (Liang et al., 2013). A another study
reported that small RNAs can quickly lead to a reduction of
miRNA levels by competition for RISC, leading to disassem-
bly of miRNAs form RISC, and ultimately causing reduction
of steady state levels of miRNAs (Pan et al., 2011). Indeed, in
our study, we found that miR30 was down-regulated upon anti-
miR21 treatment, as determined by deep-sequencing and miRNA
qPCR (Figures 3C,F). Our results indicate that perturbation
of miR30 could occur even at low anti-miR21 concentration,
such as 0.001 nM (Figure 4A). The inhibition of miR21 and
miR30 upon anti-miR21 transfection preferentially occurred in
the cytoplasm (Figures 4B,C). This ﬁnding suggested that endoge-
nous miRNAs may be replaced within the RISC complex by
exogenous antagomir because of differing afﬁnities for RISC
components, or because of competition between the miRNA
and antagomir for the RISC machinery. Another possibility is
sequence homology between anti-miR21 and miR30. To inves-
tigate how anti-miR21 regulates the expression level of miR30,
we answered the question to validate target predictions of anti-
miR21 for pri-miR30, and we aligned the sequences of anti-miR21
and pri-miR30 (Figure 8B). Surprisingly, the sequences of anti-
miR21 mostly matched the 3′ end of pri-miR30, in line with
the known effects of miRNA perturbation on knockout of PTGS
(Pan et al., 2011; Liang et al., 2013), We also noticed that anti-
miR21 is down-regulated in miR30, suggesting that anti-miR21
may bind to pri-miR30, and that this binding may disrupt the
secondary structure of pri-miR30 and prevent miRNA processing
downstream.
In conclusion, the results of our current investigation suggest
that anti-miR21 is an effective therapeutic strategy for colon cancer
by regulating miR21 pathway in nucleus and inhibiting angiogen-
esis regulated anti-miR21 as perturbing miR30. Therefore, this
study has validated anti-miR21 as a target of miR30 and demon-
strated a role for anti-miR21 in perturbing cell proliferation and
angiogenesis, two critical features of oncogenesis.
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